{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bronchopulmonary+Disease&page=5", "query": { "condition": "Bronchopulmonary Disease", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 165, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bronchopulmonary+Disease&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bronchopulmonary+Disease&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T09:21:51.766Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01030575", "title": "Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infant, Newborn", "Infant, Low Birth Weight", "Infant, Small for Gestational Age", "Infant, Premature", "Retinopathy of Prematurity", "Bronchopulmonary Dysplasia (BPD)" ], "interventions": [ { "name": "Inositol lower volume", "type": "DRUG" }, { "name": "Inositol mid-level volume", "type": "DRUG" }, { "name": "Inositol high volume", "type": "DRUG" }, { "name": "Placebo low volume", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Hours", "maximum_age": "72 Hours", "sex": "ALL", "summary": "12 Hours to 72 Hours" }, "enrollment_count": 125, "start_date": "2010-01", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01030575" }, { "nct_id": "NCT02879305", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia", "Aspergillosis, Allergic Bronchopulmonary" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2964, "start_date": "2016-09-28", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 126, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879305" }, { "nct_id": "NCT00254176", "title": "Cysteine Supplementation in Critically Ill Neonates", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Sepsis", "Bronchopulmonary Dysplasia", "Necrotizing Enterocolitis", "Retinopathy of Prematurity", "Systemic Inflammatory Response Syndrome" ], "interventions": [ { "name": "Parenteral cysteine-HCl supplementation", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo - added premasol", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Days", "sex": "ALL", "summary": "Up to 30 Days" }, "enrollment_count": 108, "start_date": "2006-09", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2010-02-26", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00254176" }, { "nct_id": "NCT03797183", "title": "Genesis Electrical Impedance Tomography (EIT): A Preliminary Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Premature Infant", "Chronic Respiratory Disease", "Neuromuscular Diseases", "Healthy", "Bronchopulmonary Dysplasia", "Pulmonary Vein Stenoses" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Days", "maximum_age": "40 Years", "sex": "ALL", "summary": "14 Days to 40 Years" }, "enrollment_count": 90, "start_date": "2019-05-03", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797183" }, { "nct_id": "NCT01222273", "title": "Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis", "Allergic Bronchopulmonary Aspergillosis" ], "interventions": [ { "name": "cholecalciferol (Vitamin D3)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 7, "start_date": "2010-09", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01222273" }, { "nct_id": "NCT04442269", "title": "Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Allergic Bronchopulmonary Aspergillosis" ], "interventions": [ { "name": "dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 62, "start_date": "2020-09-15", "completion_date": "2024-02-09", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04442269" }, { "nct_id": "NCT01748045", "title": "Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Bronchopulmonary Dysplasia" ], "interventions": [ { "name": "inhaled nitric oxide", "type": "DRUG" }, { "name": "Placebo Comparator - nitrogen gas", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Weeks", "maximum_age": "36 Weeks", "sex": "ALL", "summary": "30 Weeks to 36 Weeks" }, "enrollment_count": 3, "start_date": "2013-03", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01748045" }, { "nct_id": "NCT05364385", "title": "Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infant, Extremely Premature", "Acute Lung Injury", "Chronic Lung Disease of Prematurity", "Budesonide" ], "interventions": [ { "name": "Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)", "type": "DRUG" }, { "name": "Infants in the control group (S/P group) receive placebo (Normal saline 1mL)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Hours", "sex": "ALL", "summary": "Up to 18 Hours" }, "enrollment_count": 25, "start_date": "2019-12-02", "completion_date": "2024-12", "has_results": false, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05364385" }, { "nct_id": "NCT00215540", "title": "SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Distress Syndrome, Newborn", "Premature Birth", "Bronchopulmonary Dysplasia" ], "interventions": [ { "name": "Lucinactant 175 mg/kg", "type": "DRUG" }, { "name": "Lucinactant 90 mg/kg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Windtree Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Days", "maximum_age": "10 Days", "sex": "ALL", "summary": "3 Days to 10 Days" }, "enrollment_count": 136, "start_date": "2005-02", "completion_date": "2006-07", "has_results": true, "last_update_posted_date": "2012-06-13", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 1, "location_summary": "Warrington, Pennsylvania", "locations": [ { "city": "Warrington", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00215540" }, { "nct_id": "NCT04278404", "title": "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronavirus Infection (COVID-19)", "Pulmonary Arterial Hypertension", "Urinary Tract Infections in Children", "Hypertension", "Pain", "Hyperphosphatemia", "Primary Hyperaldosteronism", "Edema", "Hypokalemia", "Heart Failure", "Hemophilia", "Menorrhagia", "Insomnia", "Pneumonia", "Skin Infection", "Arrythmia", "Asthma in Children", "Bronchopulmonary Dysplasia", "Adrenal Insufficiency", "Fibrinolysis; Hemorrhage", "Attention Deficit Hyperactivity Disorder", "Multisystem Inflammatory Syndrome in Children (MIS-C)", "Kawasaki Disease", "Coagulation Disorder", "Down Syndrome" ], "interventions": [ { "name": "The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "0 Years to 20 Years" }, "enrollment_count": 5000, "start_date": "2020-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-09T09:21:51.766Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278404" } ] }